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Abstract
Over the past two decades, the concept of the epithelial to mesenchymal transition (EMT) has been imported from
embryology and oncology to fibrosis, particularly in the kidney. This interest in EMT in the context of renal fibrosis
stems from observations of epithelial cells undergoing phenotypic changes reminiscent of fibroblasts. Whether EMT
is actually a source of interstitial fibroblasts has been the subject of heated debate, and this controversy has caused
physicians to neglect the value of EMT as a biomarker in renal fibrosis. In this review, we describe the evolution of
the techniques used to detect EMT during fibrosing renal diseases, and what information they provide in the
diagnosis of various renal diseases. Highlighting the great heterogeneity of these techniques and the need to
standardize them, we warn against some misleading uses of EMT markers. We suggest using the association of
vimentin and b-catenin for the diagnosis of EMT in renal pathology because it is both sensitive and prognostic,
thus satisfying the properties required for a screening test. Finally, we discuss the potential interests to diagnose
EMT for the comprehension of renal fibrosis and for clinical practice.
Introduction: the concept of EMT
’What is simple is false, and what is complex is
unusable’
Paul Valéry (1941)
Since its first description by Elisabeth Hay, epithelial
to mesenchymal transition (EMT) has raised increasing
interest. One reason for this is that the concept has
extended from embryology to pathology. It was first
defined in embryological stu d i e sa sap r o c e s st h a ti s
instrumental to organogenesis, in which cells lose their
epithelial phenotype, acquire mesenchymal features, and
migrate to generate new organs in the embryo [1]. This
phenomenon, now called Type 1 EMT [2], is replicated
in Type 3 EMT, conferring on cancerous cells the ability
to disseminate by metastasis and to resist chemotherapy
[3]. Type 2 EMT refers to the rather startling concept
that epithelial cells subjected to injury may undergo
similar transformations and thus provide new fibroblasts
in the interstitium.
EMT was first associated with fibrogenesis 15 years
ago, with the observation of renal tubular epithelial cells
aberrantly expressing fibroblast-specific protein (FSP)1
in a model of mouse anti-tubular membrane disease [4].
This led Strutz et al. to hypothesize that some fibro-
blasts might be derived from transformed epithelial
cells. This hypothesis was confirmed when Iwano
showed that tubular epithelial cells bearing the reporter
gene lacZ massively contributed to the pool of intersti-
tial fibroblasts (up to 36% of all fibroblasts) in a model
of mouse renal fibrosis induced by unilateral ureteral
obstruction [5]. The study of renal EMT raised even
more interest and hopes in the nephrological commu-
nity 1 year later, when Zeisberg et al. showed that bone
morphogenetic protein (BMP)7 could reverse EMT in
mice exposed to nephrotoxic serum and even reverse
renal fibrosis itself [6].
However, several studies have subsequently contested
the reality of EMT in renal fibrosis. Fate-tracing experi-
ments on tubular epithelial cells in various animal mod-
els (Habu venom plus angiotensin 2 in rats, unilateral
ureteral obstruction or ischemia-reperfusion in mice)
failed to identify a single fibroblast originating from the
tubular epithelium [7,8]. At present, the existence of
Type 2 EMT is debated so heatedly that its supporters
and detractors seem irreconcilable [9].
In parallel, evidence has been sought for EMT in
human renal diseases, mainly using immunohistochem-
istry. Obviously, studies in patients do not allow for
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(especially the ability to migrate outside the basal mem-
brane), which is why some authors, including us, have
coined weaker terms such as ‘partial EMT’, ‘EMT-like
changes’, ‘epithelial phenotypic changes’ or ‘EMT-
marker expression’, thus avoiding the most controversial
aspect of EMT. However, the evidence for EMT-marker
expression during renal fibrosis has accumulated over
time, and we believe that a consensus can now be
reached on the presence of at least some features of
EMT during tissue fibrosis, allowing us to translate part
of the fundamental concept of EMT into clinical use as
a biomarker.
EMT: a misunderstood concept
A misinterpretation of epithelial plasticity can be traced
to the belief that an epithelial cell undergoing EMT
should become a new fibroblast. However, the definition
of EMT does not require that an epithelial cell becomes
any specific type of a cell. EMT is defined by phenotypic
and functional changes that are reminiscent of mesench-
ymal cells. This in no way means that an epithelial cell
will become a fibroblast. Strictly speaking, the term
‘mesenchyme’ is synonymous with ‘primitive connective
tissue’, that is, any tissue that 1) is neither epithelial nor
muscular nor nervous (see Ross et al, pages 54 and 115
[10]); and 2) the function of which is to provide an
extracellular matrix (ECM) used as a support for these
other cell types to function properly. As was recently
emphasized, the migration of an epithelial cell out of
the tubular structure into the interstitium where it will
produce matrix (and thereby act as a new fibroblast) is
but the ‘extreme’ form of EMT, not the essential criter-
ion for the diagnosis of EMT [9,11].
EMT reflects a global fibrogenesis
The term ‘EMT’ is by definition limited to the molecular
events occurring in epithelial cells, but the presence of
EMT reflects a more global process, affecting other cel-
lular populations. Thus, the upregulation in the epithe-
lium of the expression of mesenchymal genes is also
seen in the renal interstitium. In IgA nephropathy, focal
and segmental glomerulosclerosis or diabetic nephropa-
thy, interstitial expression of a-smooth muscle actin (a-
SMA) and FSP1 correlates with the progression of the
disease, regardless of the origin of these FSP1-positive
cells [12-14]. The reason why immunohistochemistry is
of invaluable help and of high diagnostic value is that it
is extremely sensitive in detecting the expression of
mesenchymal proteins, specifically in highly differen-
tiated epithelial cells subjected to some form of injury.
The detection of structural markers is much easier
when they are expressed de novo in cells, and more dif-
ficult when they are upregulated only in mesenchymal
cells such as fibroblasts, which already have basal
expression of such markers, in endothelial cells with a
virtual cytoplasm, or in poorly defined cell types such as
pericytes. Consistent with the idea that EMT is a part of
a global fibrogenic process, the use of DNA microarrays
has allowed quantitative measurement of the expression
of mesenchymal genes in the total cortex from renal
biopsies, and is ‘generally’ (that is, cortex-wide) upregu-
lated in fibrosing allografts [15-17]. Similarly, prelimin-
ary results indicate that mRNA expression of EMT
genes can be used as non-invasive surrogate markers for
renal fibrosis in urine, even though the origin of the
urinary cells that are being studied is not determined
[18].
FSP1: a historical but complex EMT marker
A milestone in the study of Type 2 EMT was the identi-
f i c a t i o no fF S P 1b yS t r u t zet al., which has opened the
door to the study of the epithelium as an active partici-
pant in tissue fibrosis [4]. Currently, the expression of
FSP1 by the tubular epithelium is considered to be an
incontrovertible criterion for the ‘diagnosis’ of EMT. We
believe that this should be reconsidered for three rea-
sons. First, the sensitivity of FSP1 as a fibroblast marker
has been contested, as many authentic fibroblasts do not
express it [14,19-21]. Second, its specificity is a persis-
tent matter of debate, as several studies have reported
that FSP1 can be expressed by leukocytes, particularly
macrophages [19,21-26]. Even though the antibodies
used to detect leukocytes in some of these studies have
themselves overlapping specificities, a recent publication
using a mouse model of liver injury showed that most
FSP1-positive cells stained positively for F4/80, which is
at present the most specific marker for macrophages
[21]. Even though the aberrant expression of FSP1 by
renal epithelial cells is still hi g h l ys p e c i f i ct of i b r o g e n i c
renal diseases, this does not necessarily imply that FSP1-
positive epithelial cells will generate a neofibroblast
(incidentally, this is true for all EMT markers). Thus,
although FSP1 has been shown to induce EMT in vitro
[4,27,28], facilitating the metastasis of cancer cells, the
consequences of its expression in the tubular epithelium
during fibrogenesis remain to be determined [29]. Last,
its detection by immunostaining within the renal epithe-
lium undergoing EMT is rare [4,14,30] and sometimes
technically difficult to obtain (for example, it will be
negative if the fixative used is alcohol-formalin-acetic
acid [30]). Overall, these observations disqualify FSP1 as
a usable biomarker in kidney biopsies.
Diagnosing EMT in tubular structures: practical
considerations
It is important to use multiple markers simultaneously
to detect the coordinated changes associated with EMT
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the observation of renal biopsies is possible, the migra-
tion of tubular cells outside of the basal membrane is
obviously impossible to ‘see’. Furthermore, the evidence
that tubular cells display a decrease in the expression of
epithelial markers is always questionable because the
various tubule segments differentially express the classic
epithelial proteins such as cadherins, cytokeratins and
others, even under physiological conditions [32,33]. For
example, E-cadherin is minimally expressed by proximal
tubular cells in humans, thus the assertion that E-
cadherin is lost or decreased necessarily implies that a
distal tubule is being studied [30].
By contrast with animal studies the effective clinical
diagnosis of EMT means that, rather than the loss of an
epithelial phenotype, it is the aberrant acquisition of
mesenchymal properties that is being detected in epithe-
lial cells. Two kinds of EMT markers can be used in
humans, and can be classified according to their struc-
tural (for example, changes in the composition of the
cytoskeleton) or functional (, for example, ECM produc-
tion) relevance. Schematically, the expression of struc-
tural proteins (for example, vimentin) is a feature
present in quiescent mesenchymal cells, whereas the
expression of functional proteins constitutes a feature of
activated mesenchymal cells. The heterogeneity of these
markers also has several advantages, as it allows the
detection of EMT-like changes at different stages,
depending on the characteristics of the disease and the
sensitivity and specificity needed for diagnosis (Table 1).
For example, vimentin is an intermediate-filament con-
stituent of the cytoskeleton of mesenchymal cells. Its
expression is associated with the phenotype of cells, spe-
cifically shape, motility and adhesion [34]. In tumors, it
plays a role in apoptosis, invasion and metastasis, and is
thus a new therapeutic target [35-37]. Vimentin knock-
out mice have delayed wound healing [38]. Vimentin
seems to play a role in some, but not all, models of
renal injury and repair [39,40]. It is not expressed in the
normal adult tubular epithelium, but it is strongly
expressed by by interstitial cells and the foot processes
of podocytes, and faintly by endothelial cells [41,42].
This opportunely serves as an internal positive control.
This marker lacks specificity as a mesenchymal marker,
but it is very sensitive in that vimentin staining is abso-
lutely negative in normal renal tubular cells and positive
at a very early stage after injury. Importantly, expression
of vimentin does not preclude the possibility of a rever-
sible alteration of the epithelium; the epithelial expres-
sion of vimentin was seen in a model of transient renal
injury followed by complete repair of tissue [43,44].
Regardless, the sensitivity of its detection makes it an
excellent candidate for early screening of tubular injury.
Conversely, a-SMA, a marker of activated fibroblasts,
and heat-shock protein (HSP)47, a marker of collagen
production, are less sensitive markers, but are more
clearly linked to fibrosis [45-47]. b-catenin is a marker
of particular interest here; depending on its localization
in the cell, it is either a structural epithelial marker or
a mesenchymal functional marker. Thus, whereas b-
catenin connects E-cadherin molecules to the actin
cytoskeleton in epithelial cells that behave like epithelial
cells, it may translocate in the cytosol and subsequently
into the nucleus to act as a mesenchymal transcription
factor in epithelial cells that engage in EMT. b-catenin
was actually shown to be a key activator of EMT, nota-
bly within the Wnt pathway, in various experimental
models such as ureteral obstruction, the Fisher to Lewis
allograft model of renal transplantation, and adriamycin
nephropathy [48-51]. Although any injury will probably
trigger the expression of some structural proteins char-
acteristic of fibroblasts, only an extended or repetitive
injury will lead to a functional ‘EMT’ and thereby to the
production of ECM by the surviving epithelium.
EMT in human renal disease
The expression of EMT markers in native kidneys was
investigated by Jinde on 127 patients with IgA nephro-
pathy, rapidly progressive glomerulonephritis and mini-
mal-change disease (MCD) [45]. One year later, another
study evaluated 133 renal biopsies with nine different
diagnoses [46]. Impressively, these two studies found
frequent expression of EMT markers in all the renal dis-
eases with the exception of MCD, where it was rare or
Table 1 Various combinations of epithelial to mesenchymal transition (EMT) markers used in human studies
Study EMT markers used
1
Jinde [45] a-SMA
1+, cytokeratin+, collagens+
Rastaldi [46] Vimentin+, a-SMA+, cytokeratin- ZO1-, P4H+, HSP47
3+, collagen1+
Vongwiwatana [47] E-cadherin-, cytokeratin-, vimentin+, S100A4+, a-SMA+, HSP47+
Vitalone [56] Ecadherine+, a-SMA+ OR E-cadherin+, S100A4+
Hertig [30,52,57] Vimentin+, translocation b-catenin+
1Nonexhaustive list of various combinations of markers used to detect EMT in humans. Note the contradictory criteria for EMT concerning epithelial markers.
2Smooth muscle actin.
1Heat-shock protein.
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ciated with renal disease, EMT markers were shown to
be associated with the severity of interstitial fibrosis and
the impairment of renal function [45,46]. In patients
with multiple myeloma and the highly fibrogenic condi-
tion cast nephropathy, the expression of EMT markers
was highest, including in morphologically preserved
tubules [52].
By contrast, EMT-marker expression was not found in
patients with overt proteinuria due to MCD [45,46,52],
in keeping with the fact that the high proteinuria seen
in MCD is rarely associated with interstitial fibrosis or
renal failure [53]. This strongly supports the use of
EMT as a biomarker of renal fibrogenesis. Furthermore,
in the study by Rastaldi et al., EMT markers were also
correlated with renal function in a subgroup of 45
patients with little interstitial fibrosis or infiltration,
emphasizing the excellent sensitivity of these markers
[46]. Other studies have focused on patients with one
specific renal disease. In an ingenious study, Yamaguchi
showed a correlation between EMT markers in urinary
podocytes and the severity of diabetic nephropathy [54].
Ultimately, it is in renal allografts that the association of
EMT markers with severity of renal disease has been
best documented. Vongwiwatana showed that EMT
markers were associated with serum creatinine, protei-
nuria and a history of T-cell-mediated rejection [47]. In
another set of patients with stable renal function
3 months after transplantation, we found that EMT
markers were associated with higher serum creatinine,
cold-ischemia time and subclinical acute rejection [30].
EMT markers have a prognostic value in renal
allografts
By definition, sequential biopsies are needed to study
the correlation of EMT-marker expression with fibro-
genesis, that is, with the progression of fibrosis over
time. These data are available in renal transplantation
because kidney recipients are given iterative surveillance
biopsies [55]. Two studies have evaluated the prognostic
value of EMT-marker expression in renal allografts, but
their conclusions were contradictory. The first study
showed no correlation between the expression of EMT
markers at 1 month after transplant and the presence of
tubular-interstitial injury at 3 months [56]. Our interpre-
tation is that EMT-marker expression at 1 month is
related to acute and transient factors linked to ischemia-
reperfusion injury or to the surgical transplantation pro-
cedure, with little relevance to the long-term outcome
of the graft. Moreover, in this study, EMT was defined
as staining for either FSP1 or a-SMA in a tubular cell
simultaneously stained for E-cadherin. This diagnostic
criterion is questionable, because 1) E-cadherin expres-
sion is classically downregulated during EMT and absent
in cells after complete EMT; and 2) as previously noted,
the sensitivity of a-SMA and FSP1 as EMT markers is
poor, because their late and/or rare expression during
human EMT. This choice of markers thus probably
selected for a minor population of cells. In another
study, we found that the expression of two other EMT
markers mentioned above, vimentin and b-catenin, 3
months after transplantation, do have prognostic value,
and were associated with a more rapid progression
towards graft interstitial fibrosis and decrease in renal
function at 12 months. In addition, EMT-marker
expression and interstitial or tubular inflammation were
the only factors associated with fibrosis at 12 months in
am u l t i v a r i a t ea n a l y s i s[ 5 7 ] .T h e s er e s u l t sw e r ec o n -
firmed by a recent study in which vimentin expression
within the tubular epithelium was associated with more
chronic interstitial fibrosis and tubular atrophy and with
poorer graft function, with a median follow-up of 5
years [58]. We believe that the choice of b-catenin and
vimentin is judicious, because they are expressed early
in the course of tubular injury [43,44] and the immuno-
histochemical techniques are robust (Figure 1).
Perspectives
Although EMT is a pathological process common to
many fibrosing nephropathies, the question remains as
to whether there are one or several EMTs. Currently, it
is not known if some EMT markers have a higher speci-
ficity for a specific renal disease, as studies comparing
the expression of EMT markers between various human
pathologies are few. Mechanistically, however, EMT can
be triggered by various master molecules that are each
sufficient to induce EMT [59,60]. For example, glycogen
synthase kinase 3b is a kinase that serves as a common
effector of multiple EMT pathways, facilitating the effi-
ciency of Snail and b-catenin as pro-EMT transcription
factors [61]. Hypoxia can cause EMT by inducing snail,
but snail is not specific to hypoxia, and other EMT mas-
ter genes can be induced separately by hypoxia [62-64].
Although identification of a unique ‘master switch’ [60]
would be an interesting target for the treatment of renal
fibrosis, multiple and disease-specific molecules could
be preferable as biomarkers.
Anti-EMT strategies are emerging as potential anti-
fibrotic treatments. As the two processes are closely
linked, it is difficult to determine whether a treatment is
anti-EMT or anti-fibrotic. Thus, TGF-b is known both
as an EMT inducer and as a pro-fibrotic molecule, and
in their spectacular study using BMP7 to antagonize
EMT, Zeisberg et al. showed that both tubular EMT
and fibrosis could be reversed, but they pointed out
that this association does not allow the conclusion that
fibrosis was reversed through an anti-EMT effect [6].
Nonetheless, this was probably the most promising
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showed that EMT markers were useful to monitor the
epithelial damage in vivo. Other potential anti-fibrosis
treatments have been tested for their anti-EMT effect
(for example, hepatocyte growth factor [65], paricalcitol
[49] and juglone [66-68].
Conclusions
T h e r ei ss u f f i c i e n te v i d e n c et oa s s e r tt h a ta tl e a s ts o m e
EMT markers are expressed during renal fibrosis. Such
biomarkers are very useful compared with conventional
histology, because they detect fibrogenesis as opposed to
fibrosis. They are very sensitive, and are expressed at an
early stage of the disease. This sensitivity is particularly
obvious for vimentin expression, which is currently
being translated into clinical practice in a study (clinical
trial NCT#01079143) using vimentin and b-catenin tub-
ular staining for the screening of early tubular injury in
kidney-graft biopsies. Such early markers are also useful
for renal research, as they allow characterization and
study of various models of renal injury at a stage closer
to the initiating mechanism of the disease. Second, they
are markers with reasonable prognostic value. Were an
anti-fibrotic molecule to be introduced into the pharma-
copeia, EMT markers would help in identification of
high-risk patients, and also provide a short-term
ß-catenin vimentin 
% of tubules positive:    0  <10%  10-24%  25-50  >50% 
semiquantitative  score:     0   1   2   3   4 
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Figure 1 Detection of epithelial to mesenchymal transition (EMT) by b-catenin and vimentin immunostaining, and definition of the
subsequent prognostic EMT score. Expression of the EMT markers b-catenin and vimentin in renal allograft biopsies at implantation (no EMT)
and 3 months after implantation (EMT). Note that the normal basal linear expression of b-catenin became irregular and extended to the
cytoplasm, and that vimentin was expressed de novo in the EMT-positive tubules.
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strategies. Finally, the concept of EMT has positively sti-
mulated research on adult-tissue fibrogenesis, and
helped to characterize the pro-fibrotic molecular
environment.
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